Pharmaceuticals News and Research

RSS

The rise in over the counter drugs, why?

Switching of prescription drugs to over the counter availability is increasingly common, but what are the motives behind this trend, ask US researchers in this week's BMJ?

3 Jan 2005

Is open source the answer for finding cures for tropical diseases?

Only about 1% of newly developed drugs are for tropical diseases, such as African sleeping sickness and dengue fever. While patent incentives have driven commercial pharmaceutical companies to make Western health care the envy of the world, the commercial model only works if companies can sell enough patented products to cover their R&D costs and produce profits for shareholders.

28 Dec 2004

Information submitted via new drug applications could easily be made accessible to the public

A researcher at Oregon Health & Science University and the Portland Veterans Affairs Medical Center is calling upon the U.S. Food and Drug Administration (FDA) to share more information provided by pharmaceutical companies regarding their clinical drug trials.

28 Dec 2004

Paclitaxel may benefit Alzheimer's and Parkinson's movement disorders

Angiotech Pharmaceuticals have announced that a preclinical study published in today's early edition of the Proceedings of the National Academy of Sciences highlights the positive effects of Paxceed on movement disorders commonly seen in diseases known as taupathies, such as Alzheimer's and Parkinson's.

27 Dec 2004

FDA issues not approvable letter to Cellegy Pharmaceuticals

Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).

26 Dec 2004

FDA approves Enablex for the treatment of overactive bladder

Novartis Pharmaceuticals Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Enablex® (darifenacin) extended-release tablets (7.5mg and 15mg) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.

22 Dec 2004

Pharmacogenomics, has the potential to spark a major, technology-driven restructuring of the health care and pharmaceuticals industries

Pharmacogenomics, the study of genetic variability in the way individuals respond to medicines, has the potential to spark a major, technology-driven restructuring of the health care and pharmaceuticals industries

21 Dec 2004

Tasty polymeal cuts heart disease by 76 per cent

A combined meal of seven foods including wine and chocolate could reduce cardiovascular disease by 76 per cent, a team of researchers has found.

21 Dec 2004

ChondroGene and Pfizer osteoarthritis collaboration

ChondroGene reported today that it has entered into a new two-year research collaboration with Pfizer for the identification of novel therapeutic targets and biomarkers for the treatment and diagnosis of osteoarthritis (OA).

21 Dec 2004

Dramatic changes in the way the FDA address patient safety are needed

Food and Drug Administration policies prevent pharmaceutical manufacturers from informing patients about potentially fatal toxicities that occur with some cancer drugs -- policies that should be revised immediately, according to Northwestern University researchers.

20 Dec 2004

Study on first new potential drug for tuberculosis in 40 years

454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation, announced today that its proprietary whole genome sequencing technology was used by scientists at Johnson & Johnson Pharmaceutical Research & Development L.L.C. (J&JPRD) to help understand the basis of tuberculosis drug resistance.

20 Dec 2004

Genetic markers implicated in fatal side effects of schizophrenia drug

Genaissance Pharmaceuticals today announced results from its CARING (Clozapine and Agranulocytosis Relationships Investigated by Genetics) study, reporting the discovery of genetic markers that the Company believes predict who is at risk of developing clozapine-induced agranulocytosis

20 Dec 2004

Tentative approval for Topiramate Tablets

Ranbaxy Pharmaceuticals announced tentative approval from the U.S. Food and Drug Administration to manufacture and market Topiramate Tablets, 25 mg, 100 mg, and 200 mg. Total annual market sales for Topiramate were $1,184 million with sales of these three strengths of tablets totaling $1,129 million.

20 Dec 2004

Macugen approved for the treatment of neovascular (wet) age-related macular degeneration (AMD)

Eyetech Pharmaceuticals and Pfizer have announced that the U.S. Food and Drug Administration (FDA) approved Macugen (pegaptanib sodium injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

20 Dec 2004

Ethical challenges ahead for neuroscience and society

Are we ready for a future where brain scans invade our private thoughts? Will we have to alter our brains chemically to keep competitive at our jobs? Could science determine that "souls" do not exist, and, if so, what does that mean for how we think of ourselves as human beings?

20 Dec 2004

Wine, fish, dark chocolate, fruits and vegetables cut the risk of heart disease

Scientists in this week's Christmas issue of the BMJ have discovered the 'Polymeal', a set of ingredients which cuts the risk of heart (cardiovascular) disease by 76% and significantly increases life expectancy.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004

Obesity drug codenamed AOD9604 highly successful in trials

An Australian-owned obesity drug, developed by Melbourne-based biotechnology company Metabolic Pharmaceuticals Limited, is set to enter final human trials next year after successfully completing a Phase 2b human trial which proved that the drug induces weight loss and is very well tolerated with no evidence of the side effects commonly experienced with existing obesity drugs.

16 Dec 2004

Millennium Pharmaceuticals discovers protein biomarkers that could play a role in the early detection of rheumatoid arthritis

Researchers at Millennium Pharmaceuticals today announced the discovery of a panel of protein biomarkers that could play a role in the early detection, prognosis and monitoring of rheumatoid arthritis (RA).

14 Dec 2004

Scientists have identified a novel anti-tuberculosis (TB) compound

Scientists at Johnson & Johnson Pharmaceutical Research and Development have identified a novel anti-tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection.

14 Dec 2004